USA Pricing Data
The fragmented payer system in the USA presents challenges to understanding pricing for market access and…
Category Research Papers
Explore the pinnacle of our contributions at ISPOR 2023
Our team presented five cutting-edge research posters that redefine the landscape of healthcare economics and market…
Value-based price forecasting: an accurate method for orphan drugs?
HTA decision-making for orphan drugs is a challenge. Small population sizes, limited understanding of natural history…
Importance of time horizon and analogue selection for value-based pricing of cell and gene therapies
Since the first approval of novel CGTs in 2017, patients with severe, debilitating, or life-threatening rare…
Solving the Chinese puzzle: What determines reimbursement price in China?
In China, price negotiations are mandatory for originator drugs to be listed on the National Reimbursement…
Regulatory and reimbursement landscape for Cell and Gene Therapies across Europe
Cell and gene therapies (CGTs) offer potentially curative options for previously incurable diseases; however, this comes…
Suitability of value-based price forecasting in a crowded landscape: A case study in rheumatoid arthritis
GPI attended ISPOR (November 22), in Austria Center Vienna, and had the opportunity to present four…
The relationship between value and price in the free-pricing period and post-assessment price in Germany, a case study in rheumatoid arthritis
Background As a result of the introduction of the AMNOG (Arzneimittelmarkt-Neuordnungsgesetz) law, the German healthcare system…
The National Pricing and Reimbursement Process in China: A 2021 Update
GPI attended and presented research at HTAi, held in Utrecht, Netherlands, 25-29 June 2022. GPI presented…
